Three phases, defined by clinical criteria rather than calendar dates. Lab monitoring, titration guidance, and graduation benchmarks at every stage — shaped by a decade of treating metabolic disease.
Proto360 is a physician-designed, three-phase metabolic protocol that goes beyond weight loss. Each phase builds on the last to create durable physiological change.
An aggressive but medically supervised metabolic intervention to break insulin resistance patterns and initiate meaningful weight reduction.
Transition from acute intervention to metabolic optimization — refining medication, nutrition, and behavioral protocols for sustained improvement.
Long-term metabolic maintenance designed to prevent regression. Ongoing monitoring ensures patients maintain their clinical gains.
Patients advance when their physiology says they are ready. Each phase carries defined entry conditions, a clinical focus, a monitoring cadence, and explicit graduation benchmarks.
Interrupt the drivers — insulin resistance, inflammatory load, glycemic volatility — and establish a stable, documented baseline.
Move toward target ranges across all five domains while building the behavioral capacity to hold them without clinical scaffolding.
Hold the gains at reduced clinical touch, and catch regression early enough that intervention is a conversation rather than a restart.
Metabolic disease does not respect specialty boundaries. Proto360 treats five interacting domains as a single picture rather than five separate problems handed to five different people.
Glycemic control, insulin sensitivity, lipid profile, and hepatic markers. The core disease process everything else is measured against.
Weight, lean mass retention, and visceral adiposity. Tracked together because scale weight alone cannot distinguish healthy loss from wasting.
Intake quality, protein adequacy, micronutrient status, and supplementation — phase-matched rather than prescribed once at intake.
Activity load, strength, cardiorespiratory capacity, and functional tolerance. Progressive, and deliberately protective of lean mass.
Sleep, stress load, adherence patterns, and psychological readiness. The domain that most often explains why the other four stall.
A gain in one domain at the expense of another is not progress. Scoring across all five is what separates a clinical protocol from a diet with a portal.
GLP-1 receptor agonists changed what is achievable in metabolic medicine. They also created a problem: patients who lose weight on the drug and regain it after stopping, often with worse body composition than they started.
Dose escalation follows the patient's tolerability rather than a fixed ladder, with structured symptom capture between visits so decisions rest on recorded data instead of recall at the next appointment.
Protein targets and progressive resistance loading run alongside pharmacotherapy from the first phase. This is the difference between losing fat and losing function, and it is the most common omission in drug-only programs.
Discontinuation is designed at the start, not improvised at month nine. The Sustain phase exists to make step-down survivable, with regression flagged early enough for the provider to intervene.
Proto360 was designed by physicians who have spent over a decade treating metabolic disease at one of the nation’s largest weight management organizations. Our founders are dual board-certified in Obesity Medicine and Emergency Medicine — bringing both clinical depth and operational intensity to every aspect of the protocol.
This isn’t a wellness trend adapted for clinical use. It’s a medical system built from thousands of real patient encounters, refined through evidence-based practice, and engineered to scale.
Metabolic medicine has a credibility problem, and overclaiming is most of the reason. Here is how we talk about results, including the parts that are inconvenient.
Established clinical literature on metabolic disease management, weight-management pharmacotherapy, resistance training for lean mass preservation, and behavioral adherence. The specific reference list belongs here and needs clinical sign-off before this page is published.
Outcomes are captured at the practice level and rolled up. Any figure shown on this site reflects results observed within certified practices, over a defined window, for patients who completed the phase in question.
Proto360 does not claim to cure metabolic disease, guarantee individual results, or substitute for clinical judgment. Outcomes vary with adherence, comorbidity burden, and concurrent pharmacotherapy.
Providers evaluating the protocol can request the full outcome methodology — cohort definitions, exclusion criteria, the reporting window, and how non-completers are counted. We would rather answer that question early than have it asked later.
Every aspect of Proto360 was designed by board-certified physicians with deep expertise in metabolic medicine — not adapted from consumer wellness trends.
Our protocol integrates pharmacotherapy, nutrition, behavior change, biomarker monitoring, and clinical decision support into one unified system.
Built-in measurement at every stage. Track outcomes, demonstrate ROI, and make evidence-based adjustments throughout the patient journey.
Partner with Proto360 to bring clinical-grade metabolic care to your patients, employees, or practice — backed by a complete infrastructure that handles the complexity for you.